DEF: Lifeward Ltd. Seeks Shareholder Approval for Key Governance Changes, New CEO Compensation, and Capital Expansion Amidst Declining Shareholder Returns

Lifeward Ltd. has issued its definitive proxy statement for the 2025 Annual Meeting, proposing the ratification of its new President and co-Chief Executive Officer's compensation, an increase in authorized share capital to facilitate future financing, and the approval of a new incentive compensation plan, against a backdrop of significant declines in total shareholder return and continued net losses.

Summary

• Lifeward Ltd. will hold its 2025 Annual Meeting of Shareholders on August 1, 2025, to vote on eight key proposals.
• The company is seeking to reelect three Class II directors: Mark Grant, Dr. John William Poduska, and Randel E. Richner, to serve until the 2028 annual meeting.
• Shareholders will vote to ratify the compensation package for Mark Grant, the new President and co-Chief Executive Officer, which includes a guaranteed 70% annual bonus for 2025 and an inducement grant of options to purchase 400,000 ordinary shares.
• Approval is sought for an increase in the annual fees for the Chairperson of the Board to double the amount received by other directors.
• A new 2025 Incentive Compensation Plan, authorizing 1,500,000 ordinary shares for equity awards, is proposed for approval, replacing the expired 2014 Plan.
• The company also seeks ratification of previously approved equity compensation for director Randel E. Richner for additional consulting services, involving options to purchase 90,000 ordinary shares on the approval date and 45,000 on the first anniversary, subject to the 2025 Plan's approval.
• A significant proposal is to amend the Articles of Association to increase the authorized share capital from 25,000,000 to 75,000,000 ordinary shares, intended to support future equity and debt financings.
• Shareholders will vote on the reappointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as the independent registered public accounting firm for the year ending December 31, 2025.
• An advisory Say-on-Pay vote on executive compensation is also on the agenda, following a low 18.3% approval rate in 2024, primarily influenced by one large shareholder.
• The company reported net losses of $(28.9) million in 2024, $(22.1) million in 2023, and $(19.6) million in 2022.
• Total Shareholder Return (TSR) for a $100 investment declined significantly, from $61.80 in 2022 to $63.23 in 2023, and further to $20.09 in 2024.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including persistent net losses and a sharp decline in Total Shareholder Return. Shareholder dissatisfaction with executive compensation is evident. While strategic leadership changes and a proposed capital increase aim to address future needs, the underlying financial performance and recent executive departures indicate a challenging period.

Positives

• Appointment of Mark Grant as President and co-Chief Executive Officer, bringing over 25 years of leadership experience in healthcare and medical technology, including a $1.5 billion Americas region leadership role at Medtronic.
• The proposed 2025 Incentive Compensation Plan aims to attract, retain, and motivate talented and qualified employees, directors, and consultants, which is crucial for continued growth.
• The proposed increase in authorized share capital to 75,000,000 ordinary shares provides flexibility for future equity and debt financings, which is essential for funding operating costs and potential growth initiatives.
• The company has a clawback policy for incentive compensation, aligning with Dodd-Frank Act requirements, which promotes accountability.
• The Board has separated the roles of CEO and Chairperson, which is generally considered a good corporate governance practice, allowing for better focus and objective evaluation.
• The Board has determined that most of its directors are independent under Nasdaq listing standards, indicating strong governance oversight.
• The audit committee includes two financial experts (Robert Marshall and Hadar Levy), enhancing financial oversight.
• The company has a distribution agreement with CorLife (a Numotion subsidiary) for the ReWalk Personal Exoskeleton, indicating commercialization efforts.

Negatives

• Significant decline in Total Shareholder Return (TSR), with a $100 investment on December 31, 2021, decreasing to $20.09 by the end of 2024.
• Continued net losses: $(28.9) million in 2024, $(22.1) million in 2023, and $(19.6) million in 2022, indicating ongoing unprofitability.
• Low shareholder approval for the Say-on-Pay vote on executive compensation in 2024 (18.3% in favor), reflecting shareholder dissatisfaction, primarily from a large institutional shareholder.
• The 2024 Incentive Compensation Plan was not approved by shareholders, leading to no RSU grants in 2024 and necessitating a new 2025 plan.
• Resignation of Michael Lawless as Chief Financial Officer and Principal Financial Officer, effective June 27, 2025.
• Charles Remsberg ceased to serve as Chief Sales Officer effective May 15, 2025.
• The need to increase authorized share capital suggests a potential need for significant future capital raises, which could lead to shareholder dilution.
• The compensation for the former CEO, Larry Jasinski, was significantly higher in 2023 ($888,683 total compensation, $860,554 actually paid) compared to 2024 ($473,274 total, $278,821 actually paid), despite continued net losses and declining TSR.

Risks

• Financial Performance Risk: Continued net losses and declining Total Shareholder Return (TSR) indicate ongoing financial challenges and a risk to profitability and shareholder value.
• Capital Raising Risk: The need to increase authorized share capital to 75,000,000 shares suggests potential future equity issuances, which could dilute existing shareholders' ownership.
• Shareholder Dissatisfaction Risk: The low approval rate for the Say-on-Pay vote (18.3% in 2024) indicates significant shareholder dissatisfaction with executive compensation, which could lead to further governance challenges or activist investor engagement.
• Executive Transition Risk: The resignation of the CFO and the former Chief Sales Officer, coupled with the transition of the CEO role, introduces potential operational and leadership continuity risks.
• Incentive Plan Approval Risk: Failure to approve the proposed 2025 Incentive Compensation Plan could hinder the company's ability to attract, retain, and motivate key talent through equity awards.
• Regulatory Compliance Risk: As an Israeli company, Lifeward Ltd. must comply with both U.S. SEC regulations and Israel Companies Law, adding complexity to corporate governance and compliance.
• Market Acceptance/Reimbursement Risk: The document mentions Randel E. Richner's consulting services related to CMS and third-party insurers, indicating ongoing efforts and potential challenges in securing reimbursement for products like the ReWalk Personal Exoskeleton.

Future Outlook

The company intends to finance operating costs over the next twelve months with existing cash on hand, potential reduction in operating cash burn, and future issuances of equity and debt securities, or through a combination of the foregoing. They will seek additional sources of financing if more funds are needed than anticipated during the next 12 months or in later periods.

Management Comments

• "We intend to hold the Meeting in person. In the event it is not possible or advisable to hold the Meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication."
• "For the reasons set forth in the accompanying Proxy Statement, our Board of Directors recommends that you vote FOR Proposals 1 8 on the agenda for the Meeting."
• "Mr. Grant has extensive knowledge and experience in the field of the Companys activities and has the ability to contribute significantly to the advancement of the Company's business."
• "The compensation offered to Mr. Grant is in line with the scope of his employment and the responsibilities imposed on a CEO of a company by virtue of his position, is appropriate for the size of the Company, the scope of its activities and nature, and is suitable for promoting its goals, its work plans and goals and the desire to retain a worthy CEO for the Company, and reflect reasonable and fair terms of office."
• "The proposed equity award to Mr. Grant described above reinforces the identity of interests between the CEO and the shareholders of the Company and is an incentive to promote the Companys long-term goals and objectives."
• "Our Board of Directors was disappointed with the 2024 result [of the Say-on-Pay vote]."
• "Based on feedback from our shareholders, we understand that concerns with our executive compensation program related primarily to the link between CEO compensation and Company performance."
• "We intend to continue engaging with our shareholders and reviewing our compensation and governance practices in the future."

Industry Context

The document highlights Lifeward Ltd.'s focus on healthcare and medical technology, specifically mentioning the ReWalk Personal Exoskeleton and efforts related to CMS and third-party insurer reimbursement. The appointment of Mark Grant from Medtronic and IMRA Surgical, and Michael Swinford from GE Healthcare and Numotion, indicates a strategic focus on experienced leaders in the medical device and rehabilitation sectors. The challenges in securing reimbursement (as implied by Randel Richner's consulting) suggest a complex regulatory and market access environment common in the medical device industry. The company's financial performance (net losses, declining TSR) contrasts with the general growth potential often associated with innovative medical technologies, suggesting specific company-level challenges or intense market competition.

Comparison to Industry Standards

• The document does not provide specific comparable companies or projects for direct comparison of financial results or operational performance.
• It mentions that executive compensation is "competitive within our industry, consistent with executive compensation of companies similarly sized and with similar complexities," but does not name specific comparable companies or benchmarks.
• The low Say-on-Pay vote (18.3%) suggests that shareholders perceive the executive compensation as not aligned with company performance, which is a significant deviation from typical shareholder approval rates for executive compensation in well-performing companies.
• The decline in TSR from $61.80 in 2022 to $20.09 in 2024 for a $100 investment indicates underperformance relative to a stable or growing market, though no specific industry benchmark is provided.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting Agreement with Richner Consultants, LLC (owned by Randel E. Richner, a director): Ms. Richner provided additional consulting services beyond her director duties in 2022, 2023, and early 2024, primarily related to CMS and reimbursement. She is to be compensated $297,000 for these excess hours in the form of equity compensation (options to purchase 90,000 ordinary shares initially and 45,000 on the first anniversary of approval), subject to shareholder approval of the 2025 Incentive Compensation Plan.
• Distribution Agreement with CorLife: On March 6, 2025, Lifeward Ltd. announced an exclusive distribution agreement with CorLife (a subsidiary of Numotion) for the ReWalk Personal Exoskeleton for workers' compensation claims. Michael Swinford, a member of Lifeward's Board, serves as the CEO of Numotion. The Board reviewed and approved the financial terms, which were negotiated at arm's length.

Stakeholder Impact

• Shareholders: Directly impacted by proposals regarding director elections, executive compensation, incentive plans (potential dilution from new shares), and the significant increase in authorized share capital (potential future dilution from capital raises). The declining TSR and net losses are a negative impact.
• Employees: Impacted by the proposed 2025 Incentive Compensation Plan, which aims to attract and retain talent through equity awards. Executive changes (new CEO, CFO resignation, CSO departure) could affect morale and organizational stability.
• Customers: The distribution agreement with CorLife for the ReWalk Personal Exoskeleton could expand access to the product for individuals with workers' compensation claims.
• Management: Directly impacted by compensation proposals, changes in roles (new CEO, departing CFO/CSO), and the strategic direction set by the Board.
• Creditors: The proposal to increase authorized share capital suggests potential future debt or equity financing, which could impact the company's capital structure and ability to meet obligations.

Next Steps

• Hold the 2025 Annual Meeting of Shareholders on August 1, 2025.
• Shareholders to vote on the reelection of three Class II directors.
• Shareholders to vote on the ratification of Mark Grant's compensation.
• Shareholders to vote on the approval of annual fees for the Chairperson of the Board.
• Shareholders to vote on the approval of the 2025 Incentive Compensation Plan.
• Shareholders to vote on the ratification of Randel E. Richner's equity compensation.
• Shareholders to vote on the increase in authorized share capital.
• Shareholders to vote on the reappointment of Kost Forer Gabbay & Kasierer as independent registered public accounting firm.
• Shareholders to cast an advisory (Say-on-Pay) vote on executive compensation.
• The Board will provide a management report and review 2024 financial statements at the meeting.
• The company plans to announce preliminary voting results at the Meeting and file final results in a Form 8-K within four business days.
• The compensation committee intends to take into account the outcome of the Say-on-Pay vote when considering future executive compensation decisions.
• The company will continue engaging with shareholders and reviewing compensation and governance practices.
• Potential future issuances of equity and debt securities to finance operating costs.

Key Dates

Keywords

Lifeward Ltd., SEC filing, DEF 14A, Proxy Statement, Annual Meeting, Shareholder Vote, Corporate Governance, Executive Compensation, Incentive Compensation Plan, Authorized Share Capital, Capital Raise, Net Loss, Total Shareholder Return, CEO Transition, CFO Resignation, Director Election, Related Party Transactions, Medical Technology, Exoskeleton, Reimbursement